Phase 2 pilot study evaluates ticagrelor monotherapy safety after stenting for acute MI

This is a single-center, single-arm, prospective phase II pilot study designed to evaluate the initial safety of ticagrelor monotherapy following coronary artery stenting for acute myocardial infarction. The study enrolled 200 patients who underwent stenting due to either NSTEMI or STEMI. All patients underwent invasive coronary angiography and clinically indicated Percutaneous Coronary Intervention (PCI), which was performed using EES (everolimus-eluting stents) and OCT guidance utilizing the MLDMAX algorithm (Morphology, Length, Diameter, Medial dissection, Apposition, Xpansion). Eligibility was assessed after PCI completion. Patients were provided a drug diary to document and remind them of twice-daily ticagrelor 90mg administration. A Data Safety Monitoring Board (DSMB) was tasked with continuously reviewing patient outcomes. The DSMB was scheduled to convene after the first 50 patients were recruited and at least 30 of those patients had either reached the 3-month follow-up or experienced the primary outcome. The primary endpoint for the study was the composite of cardiac death, spontaneous myocardial infarction, or definite or probable stent thrombosis occurring within 3 months. The study, led by the Vastra Gotaland Region, started on December 14, 2021, and had a primary completion date of June 26, 2025. The abstract does not report any results, safety data, or statistical outcomes from the study.

If you've had a heart attack and needed a stent, you know the drill: you leave the hospital with a fistful of medications. This study is asking a big question: what if one of those pills could do the job on its own? Doctors are running a pilot study to see if taking just ticagrelor—a powerful blood thinner—is a safe way to prevent more heart trouble after getting a stent for a heart attack (whether it's the kind called NSTEMI or STEMI). They're enrolling 200 people who have the procedure. The main thing they're watching for is a combination of the worst outcomes: death from heart problems, another spontaneous heart attack, or a blood clot forming in the new stent. They'll track everyone for three months. A special safety board is keeping a close eye on the results, especially after the first 50 people finish the study. The goal is to gather initial safety data on this simpler, one-drug strategy. If it proves safe in this pilot, it could pave the way for larger tests to see if it's just as effective as taking multiple drugs, potentially making recovery simpler for patients.